Cargando…
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury. Clinical trials focusing o...
Autores principales: | Huang, Li-Kai, Kuan, Yi-Chun, Lin, Ho-Wei, Hu, Chaur-Jong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544555/ https://www.ncbi.nlm.nih.gov/pubmed/37784171 http://dx.doi.org/10.1186/s12929-023-00976-6 |
Ejemplares similares
-
Clinical trials of new drugs for Alzheimer disease
por: Huang, Li-Kai, et al.
Publicado: (2020) -
Clinical Trials of New Drugs for Vascular Cognitive Impairment and Vascular Dementia
por: Linh, Tran Thanh Duy, et al.
Publicado: (2022) -
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
por: McFarthing, Kevin, et al.
Publicado: (2023) -
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
por: Yadollahikhales, Golnaz, et al.
Publicado: (2023) -
Alzheimer's disease drug development pipeline: 2023
por: Cummings, Jeffrey, et al.
Publicado: (2023)